VAQTA Adult, Suspension for injection

Similar documents
Some general information on hepatitis A infection is given at the end of this leaflet.

PACKAGE LEAFLET: INFORMATION FOR THE USER

เอกสารกาก บยาภาษาอ งกฤษ. AVAXIM 160 U Suspension for injection in a prefilled syringe Hepatitis A vaccine (inactivated, adsorbed)

Package leaflet: Information for the user. HBVAXPRO 10 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)

Havrix Monodose Vaccine Hepatitis A Vaccine (Inactivated, adsorbed) ELISA Units/1 ml Suspension for Injection in a pre-filled syringe

PACKAGE LEAFLET: INFORMATION FOR THE USER. AVAXIM, Suspension for injection in a pre-filled syringe Hepatitis A vaccine (inactivated, adsorbed)

PACKAGE LEAFLET: INFORMATION FOR THE USER. Pneumococcal Polysaccharide Vaccine

Package leaflet: Information for the user REPEVAX. Suspension for injection in pre-filled syringe

Package leaflet: Information for the user

Package leaflet: Information for the user. HBVAXPRO 5 micrograms, suspension for injection in pre-filled syringe Hepatitis B vaccine (rdna)

TYPHIM Vi, Solution for injection

ACT-HIB powder and solvent for solution for injection Haemophilus influenzae type b Conjugate Vaccine

Package Leaflet: Information for the user

Package leaflet: Information for the user

D-Gam 250 micrograms/ml. Solution for injection. human anti-d immunoglobulin

Package leaflet: Information for the user. HBVAXPRO 40 micrograms, suspension for injection Hepatitis B vaccine (rdna)

Package leaflet: Information for the user

Package leaflet: Information for the user. Poliomyelitis Vaccine (Inactivated) suspension for injection in pre-filled syringe

Package leaflet: Information for the user Priorix, powder and solvent for solution for injection in a pre-filled syringe

Package leaflet: Information for the user. REVAXIS Suspension for injection in pre-filled syringe

Package Leaflet: Information for the user. Prevenar 13 suspension for injection Pneumococcal polysaccharide conjugate vaccine (13 valent, adsorbed)


PACKAGE LEAFLET: INFORMATION FOR THE USER

IMPORTANT: PLEASE READ

Package leaflet: Information for the user

Package leaflet: Information for the user

SINGULAIR JUNIOR 5mg chewable tablets

Suspension for injection in pre-filled syringe Diphtheria, tetanus and pertussis (acellular component) vaccine (adsorbed, reduced antigen content)

PACKAGE LEAFLET: INFORMATION FOR THE USER. DUKORAL suspension and effervescent granules for oral suspension Cholera vaccine (inactivated, oral)

Package leaflet: Information for the user. Bupivacaine 0.25% w/v, 0.5% w/v solution for injection Bupivacaine Hydrochloride

1 What Engerix B is and what it is used for

Package leaflet: information for the user

NeisVac-C Meningococcal group C polysaccharide conjugate vaccine (tetanus toxoid protein conjugate)

Gammaplex 2.5 g, 5 g, 10 g and 20 g 5% w/v solution for infusion human normal immunoglobulin

Package leaflet: Information for the user. Haemophilus type b and Meningococcal group C conjugate vaccine

Package leaflet: Information for the patient

Package leaflet: Information for the user

IMOJEV Japanese encephalitis vaccine (live, attenuated)

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user

RABEPRAZOL 10mg and 20mg Gastro-resistant Tablets

PACKAGE LEAFLET: INFORMATION FOR THE USER

Package leaflet: Information for the user. Elaprase 2 mg/ml concentrate for solution for infusion idursulfase

HEALTHCARE SUPPLIES SPECIALISTS. Product information. amaproducts.com.au HEALTHCARE SUPPLIES SPECIALISTS

Package leaflet: Information for the user. Exembol 1 mg/ml solution for infusion. argatroban monohydrate

IMOVAX POLIO POLIOMYELITIS VACCINE (INACTIVATED) Suspension for injection in prefilled syringe

PATIENT / USER INFORMATION LEAFLET. Cinryze 500 Units powder and solvent for solution for injection C1 inhibitor (human)

SINGULAIR 10mg film-coated tablets

Package leaflet: Information for the user

GARDASIL 9 [Human Papillomavirus 9-valent Vaccine, Recombinant] Consumer Medicine Information

Package leaflet: Information for the patient. SYLVANT 400 mg powder for concentrate for solution for infusion. siltuximab

HAVRIX 1440 and HAVRIX Junior

PATIENT INFORMATION LEAFLET

Help keep hepatitis A and B out of your travel plans.

PACKAGE LEAFLET: INFORMATION FOR THE USER. GRAZAX 75,000 SQ-T oral lyophilisate

HEPATYRIX (Combined inactivated hepatitis A and Vi polysaccharide typhoid vaccine) CONSUMER MEDICINE INFORMATION LEAFLET

HERNOVIR 200 mg tablets

If you have any concerns about being given this vaccine, ask your doctor.

Package leaflet: Information for the patient. Vyxeos 44 mg/100 mg powder for concentrate for solution for infusion daunorubicin and cytarabine

Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Package leaflet: Information for the patient. Bumetanide 1 mg and 5 mg Tablets (bumetanide)

Package leaflet: information for the user

1. What Panzyga is and what it is used for

Package leaflet: Information for the user

NORVASC 5 mg and 10 mg tablets

Package leaflet: Information for the user. Portrazza 800 mg concentrate for solution for infusion necitumumab

Package leaflet: Information for the user

MENACTRA Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine

VIVAXIM Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine

KAMIREN PACKAGE LEAFLET: INFORMATION FOR THE USER. What is in this leaflet? 1. WHAT KAMIREN IS AND WHAT IT IS USED FOR

Package leaflet: Information for the user

Package leaflet: Information for the patient. Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam

Package leaflet: Information for the user. Cefixime ABR 100 mg/5 ml powder for oral suspension Cefixime

Package leaflet: Information for the user. Cinfalair 4 mg chewable tablets montelukast

Package leaflet: Information for the user

Package leaflet: Information for the patient. Gemcitabine 10 mg/ml, solution for infusion. gemcitabine

Your treatment with XELJANZ

BCHOOSE TO VACCINATED. Ask your doctor about the MenB * vaccine.

Package leaflet: Information for the user. Zoledronic Acid Accord 4 mg/5 ml concentrate for solution for infusion Zoledronic acid

VIVAXIM. Salmonella typhi Vi polysaccharide and inactivated hepatitis A virus antigen vaccine. Consumer Medicine Information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Calcium Folinate 10 mg/ml Injection

Aciclovir Apotex 200 mg tabletten RVG Package leaflet: Information for the user Aciclovir Apotex 200 mg tabletten Aciclovir

2. What you need to know before Marcain Polyamp Steripack is given to you

OncoTICE powder for suspension 2-8 X 10 8 CFU Tice BCG. 1. What Oncotice is and what it is used for. 2. Before you are given Oncotice

Influvac Inactivated influenza vaccine [surface antigen]

ADACEL POLIO. This leaflet answers some common questions about ADACEL POLIO. It does not take the place of talking to your doctor or pharmacist.

If you have any concerns about ENGERIX-B talk to your doctor, nurse or pharmacist.

Package leaflet: Information for the user Zinforo 600 mg powder for concentrate for solution for infusion Ceftaroline fosamil

Package leaflet: Information for the patient. Loratadine 10 mg Tablets (loratadine)

Normal Immunoglobulin (Human) 16%, solution for subcutaneous administration.

Package leaflet: Information for the user. /.../ 50 mg powder and solvent for solution for injection/infusion. melphalan

Package leaflet: Information for the user. Cinfalair Paediatric 4 mg Granules montelukast

FluQuadri ; FluQuadri Junior Inactivated Quadrivalent Influenza Vaccine (Split Virion)

Package leaflet: Information for the user. Tobramycin 40 mg/ml Solution for Injection tobramycin

If you have any concerns about being given this vaccine, ask your doctor or pharmacist.

Package leaflet: Information for the user

Transcription:

Package Leaflet: Information for the User VAQTA Adult, Suspension for injection Hepatitis A vaccine, inactivated, adsorbed. For Adults Read all of this leaflet carefully before you are vaccinated because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor, pharmacist or nurse. This vaccine has been prescribed for you only. Do not pass it on to others. If you get any side effects talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What Vaqta Adult is and what it is used for 2. What you need to know before Vaqta Adult is given 3. How Vaqta Adult is given 4. Possible side effects 5. How to store Vaqta Adult 6. Contents of the pack and other information 1. What VAQTA Adult is and what it is used for. Vaqta Adult is one of a general group of medicines called vaccines. Vaccines are used to protect against infectious diseases. They work by causing the body to produce its own protection against the targeted disease. This vaccine helps to protect against hepatitis A infection. Hepatitis A is a virus that attacks the liver, which can be caught from food or drink that contains the virus. Symptoms of hepatitis A include a yellowing of the skin and eyes (jaundice) and feeling generally unwell. When an injection of this vaccine is given, the body's natural defences will produce protection (antibodies) against the hepatitis A infection. However, it usually takes 2 to 4 weeks after receiving the injection before you will be protected. This vaccine will not protect you against other viruses that infect the liver (such as hepatitis B, hepatitis C or hepatitis E). This vaccine protects against hepatitis A but cannot cause hepatitis A infection.

The vaccination may not work properly if the person to be vaccinated is already infected with the hepatitis A virus. Vaqta Adult is for adults aged 18 years and over. This vaccine is not suitable for anyone younger than 18 years of age. 2. What you need to know before VAQTA Adult is given Do not use Vaqta Adult: if you are allergic to the active substance or any of the other ingredients of Vaqta Adult (listed in section 6) or to neomycin or formaldehyde (see section "Warnings and precautions"). if you are ill with a high temperature. The vaccination should be delayed until you have recovered. Warnings and precautions Talk to your doctor, pharmacist or nurse before Vaqta Adult is given: if you have ever had an allergic reaction to a previous dose of Vaqta Adult. This vaccine may contain traces of an antibiotic called neomycin and a substance called formaldehyde, both of which are used during vaccine production and may be present in the vaccine in trace amounts. if you have a poor or reduced immune system, due to: corticosteroids, cytotoxic drugs or radiotherapy. Your doctor or nurse may wait until the treatment has finished. HIV (human immunodeficiency virus infection) or any disease that affects the immune system. The vaccine may not protect as well as it protects people whose immune system is healthy. if you have any problems with the blood that causes easy bruising or bleeding for a long time after minor cuts. Your doctor or nurse may still advise that you should have Vaqta Adult but extra care is needed because of the risk of bleeding at the injection site. Your doctor or nurse may give Vaqta Adult as an injection under the skin instead of into muscle (see section 3) to try to reduce the risk of deep bleeding. The container of this medicinal product contains latex rubber. May cause severe allergic reactions. As with other vaccines, Vaqta Adult may not completely protect all persons who are vaccinated. Please tell your doctor if you have a history of jaundice or have lived in an area where hepatitis A is common. Your doctor will determine whether you should be tested for hepatitis A antibodies prior to vaccination.

Other medicines and VAQTA Adult Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines (or other vaccines). This vaccine can be given at the same time as any of the following provided that they are given in different parts of the body (for example another arm) and are not mixed in the same syringe. Vi polysaccharide typhoid vaccine, Yellow fever vaccine, Immunoglobulins (antibodies obtained from blood donors) Studies with a paediatric formulation have shown that the vaccine may be given at the same time as measles, mumps, rubella, varicella, pneumococcal 7-valent conjugate, inactivated polio, diphtheria toxoid, tetanus toxoid, acellular pertussis or Haemophilus influenzae type b vaccines. Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice whether you should receive the vaccine. Driving or using machines There are no data to suggest that Vaqta Adult affects the ability to drive or operate machinery. Vaqta Adult contains less than 1 mmol sodium (3.55 mg) per dose i.e. essentially sodium-free. 3. How VAQTA Adult is given The vaccine will be injected by a doctor or nurse who has been trained in the use of vaccines and who is equipped to deal with any rare severe allergic reaction to the injection. Short term protection against hepatitis A is achieved within 2 to 4 weeks after receiving this vaccination. This may take a little longer if the injection is given under the skin, rather than into the muscle. Long-term protection against hepatitis A requires a second dose (booster injection) of an inactivated hepatitis A vaccine. This is usually given between 6 and 18 months after the first dose. This booster will protect you against hepatitis A for at least 6 years. It is predicted that hepatitis A antibodies will remain at least 25 years after vaccination. If necessary, Vaqta Adult can be given as a booster injection 6 to 12 months after you received a first dose of another inactivated hepatitis A vaccine.

Method of administration The doctor or nurse will shake the syringe immediately before use and check that the liquid is white and cloudy and that there are no large particles. The vaccine is given as an injection into a muscle in the upper outer part of the arm. Your doctor or nurse will avoid giving you the injection either into the skin or into a blood vessel. People who are at risk of bleeding a lot after an injection (see section 2) may sometimes be given Vaqta Adult as an injection under the skin but not into muscle to try to reduce the risk of bleeding. Use in children and adolescents Vaqta Adult is not recommended for individuals less than 18 years of age. 4. Possible side effects Like all medicines and vaccines, this vaccine can cause side effects, although not everybody gets them. As with all vaccines, allergic reactions, in rare cases leading to shock, may occur. These reactions may include: - hives - difficulty in breathing - swelling of the face, tongue and throat - dizziness - collapse. When these signs or symptoms occur they usually develop very quickly after the injection is given and while you are still in the clinic or doctor s surgery. If any of these symptoms occurs after leaving the place where you received the injection, contact a doctor IMMEDIATELY. Frequency of side effects Very common: may affect more than 1 in 10 people Common: may affect up to 1 in 10 people Uncommon: may affect up to 1 in 100 people Side effects injection-site tenderness, pain, warmth, swelling, redness - headache - arm pain (in the injected arm) - weakness/tiredness, fever (38.3 C or over), bleeding under the skin at the injection site (ecchymosis), pain and soreness - sore throat, upper respiratory infections - swelling of the lymph nodes - dizziness, abnormal skin sensations such as tingling - ear ache - hot flushes - runny or blocked nose and airways, cough

- feeling sick (nausea), diarrhoea, excessive gas in the stomach and intestines, vomiting - hives, itching, redness - muscle pain, stiffness, shoulder pain, musculoskeletal pain (pain that affects the muscles, ligaments and tendons, along with the bones) back pain, joint pain, leg pain, neck pain, muscle weakness - itching at the injection-site, stiffness/tightness, pain, bruising at the injection-site, chills, stomach ache, feeling generally unwell, hardness (induration) and numbness at the injection-site, cold sensation, flu-like illness Rare: may affect up to 1 in 1,000 people Not known: frequency cannot be estimated from the available data - bronchitis, inflammation of the stomach and intestines (gastroenteritis) - loss of appetite - lacking energy, trouble sleeping - sleepiness, migraine, tremor - itching eyes, sensitivity to light, increased flow of tears - vertigo - swelling of the throat, problems with the sinuses - dryness of the mouth, mouth ulcers - night sweats, rash, skin disorders - muscle cramp, elbow pain, hip pain, jaw pain, spasm - problems with periods - injection-site burning, lump ( 2.5 centimetres), muscle twitching, rash, swelling of the stomach, chest pain, pain in the side; irritability - Guillain-Barré syndrome (muscle weakness, abnormal sensations, tingling in the arms, legs and upper body) - thrombocytopenia (reduction in blood platelets which increases risks of bleeding and bruising) Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store VAQTA Adult Keep this vaccine out of the sight and reach of children. The vaccine should not be used after the expiry date (Exp) which is stated on the carton and syringe or vial label. The vaccine must be stored in a refrigerator between 2 C and 8 C (making sure that it does not freeze) so that the vaccine keeps its effectiveness. Do not use this vaccine if you notice that it has an unusual appearance (see section 6) or contains particulate matter. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment. 6. Contents of the pack and other information What Vaqta Adult contains The active ingredient is: Inactivated hepatitis A virus (produced on MRC-5 human diploid cells, adsorbed on aluminium hydroxyphosphate sulphate). One dose (1 ml) contains 50U hepatitis A virus (inactivated) adsorbed on aluminium hydroxyphosphate sulphate (0.45 milligram as aluminium). The other ingredients are: sodium borate sodium chloride water for injections What Vaqta Adult looks like and contents of the pack A pre-filled syringe or vial containing 1 millilitre (one dose) of the vaccine. The vaccine is available in single packs of the vial or pre-filled syringe with or without a needle. Not all presentations may be marketed. After thorough agitation Vaqta Adult is an opaque white suspension. Marketing Authorisation Holder The Marketing Authorisation Holder in the UK is: Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom

Manufacturer The manufacturer responsible for batch release at the following manufacturing sites is: Merck Sharp and Dohme B.V., Waarderweg 39, PO Box 581, 2003 PC Haarlem, Netherlands This leaflet was last revised in January 2017. Merck Sharp & Dohme Limited, 2017. All rights reserved. PIL.VAQ-A.16.UK.4931-COO ----------------------------------------------------------------------------------------------------------- The following information is intended for healthcare professionals only: Incompatibilities In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Instructions for use and handling The vaccine should be used as supplied. The vaccine should be inspected visually prior to administration for any foreign particulate matter and/or abnormal physical appearance. Discard the product if particulates are present or if it appears discoloured. The syringe should be well shaken until a slightly opaque white suspension is obtained. Thorough agitation is necessary to maintain suspension of the vaccine. For syringe without attached needle, hold the syringe barrel and attach the needle by twisting in clockwise direction until the needle fits securely on the syringe and give the vaccine immediately. Merck Sharp & Dohme Limited, 2017. All rights reserved. PIL.VAQ-A.16.UK.4931-COO